Q3 was filled with grant writing, prototype development, and setting up our first large human subject research study.
The Resilient team moved offices and received some great publicity in June
I moved from Austin to Pittsburgh because Pittsburgh’s a great city to work in
Charlie responds to the Pennsylvania State Senate's decision to ban safe consumption facilities in the state
In Spring 2023, the FDA approved two significant products: (1) the Masimo Opioid Halo and (2) the first OTC naloxone nasal spray. Read about how this impacts Resilient's business.
We made some great technical progress and began applying for nondilutive funding